Crossmark

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study

Crossref DOI link: https://doi.org/10.1186/s12888-020-02636-7

Published Online: 2020-05-08

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Levada, Oleg A.

Troyan, Alexandra S. http://orcid.org/0000-0002-6160-4604
Pinchuk, Irina Y.
License Information

Text and Data Mining valid from 2020-05-08

Version of Record valid from 2020-05-08
More Information

Article History

Received: 2 May 2019

Accepted: 30 April 2020

First Online: 8 May 2020

Ethics approval and consent to participate

: Ethics approval was obtained from the Zaporizhzhia Medical Academy of Postgraduate Education Ethics Committee - Zaporizhzhia, Ukraine, on 15th September 2016. All participants provided written informed consent.

: Not applicable.

: O.A. Levada is a member of advisory and/or speaker boards of the following companies: Lundbeck, Pfizer, Acino. A.S. Troyan gave presentations for Lundbeck and Acino.

Document is current

Any future updates will be listed below